3130-87-8

Usage

Uses

1. Used in Pharmaceutical Industry:
DL-Asparagine monohydrate is used as a raw material for the synthesis of various pharmaceutical compounds, such as DL-asparaginium perchlorate, DL-asparaginium nitrate, and dimethyl DL-aspartate. These synthesized salts have potential applications in the treatment of certain medical conditions.
2. Used in Biotechnology and Microbiology:
DL-Asparagine monohydrate serves as a growth-promoting agent in the growth media for bacteria. It is particularly useful in the cultivation of microorganisms that require asparagine for their growth and development.
3. Used in Chemical Synthesis:
DL-Asparagine monohydrate is used as a starting material or intermediate in the synthesis of various chemical compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
4. Used in Research and Development:
Due to its unique chemical properties, DL-Asparagine monohydrate is utilized in research and development for studying the structure, function, and interactions of amino acids and their derivatives in biological systems.

Preparation

DL-Asparagine monohydrate was synthesized by dissolving maleic anhydride in 1,4-dioxane solution and refluxing with benzylamine after ammonolysis, followed by catalytic hydrogenation.

InChI:InChI=1/C4H8N2O3.H2O/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H2,6,7)(H,8,9);1H2

Upstream product

• 108-31-6 maleic anhydride 
• 21860-86-6 aspartic acid 4-ethyl ester 
• 43101-48-0 DL-aspartic acid diethyl ester 
• 303-24-2 N-phthaloyl-asparagine 
• 70-47-3 L-asparagine 
• 77287-34-4 formamide 
• 302-72-7 rac-Ala-OH 
• 56-84-8 L-Aspartic acid 
• 6232-19-5 β-cyano-L-alanine 

Downstream Products

• 6630-35-9 N²-(2-bromo-propionyl)-asparagine 
• 93923-85-4 N²-formyl-asparagine 
• 35181-18-1 N²-(N,N-phthaloyl-glycyl)-DL-asparagine 
• 5624-08-8 D,L-asparagine N-phenylthiohydantoin 
• 36212-66-5 N²-(toluene-4-sulfonyl)-L-asparagine 
• 105086-77-9 N^α-[(2,4-dichloro-phenoxy)-acetyl]-DL-asparagine 
• 2752-49-0 N²-phenylacetyl-asparagine 
• 75-07-0 acetaldehyde 
• 138995-91-2 2-(5-Benzyl-6-thioxo-[1,3,5]thiadiazinan-3-yl)-succinamic acid 
• 139765-48-3 3-(2-Phenylethyl)-5-<α-(carbamidomethyl)carboxymethyl>-tetrahydro-2H-1,3,5-thiadiazine-2-thione 
• 70-55-3 toluene-4-sulfonamide 
• 107-91-5 cyanoacetic acid amide 
• 2058-58-4 (R)-Asparagine 
• 70-47-3 L-asparagine 

Relevant academic research and scientific papers

Preparation and purification method of amino acid compound

The invention relates to the field of industrial organic synthesis, in particular to a preparation and purification method of an amino acid compound. The method comprises the following steps that (1)alpha-amino nitrile compounds or hydantoin compounds or mixtures thereof are heated to react to obtain alpha-amino acid salt under the condition that volatile alkali and a suitable solvent exist; (2)after the alpha-amino acid salt obtained in step (1) is distilled, the alpha-amino acid salt is recrystallized in an organic solvent to obtain the alpha-amino acid compound. According to the method, reaction conditions are mild, materials can be recycled, and introduction of metal ions and use of ammonium carbonate salt are avoided, so that post-treatment is simple and no waste salt is generated.

Degradation of complexons derived from succinic acid under UV radiation

The destruction of complexons derived from succinic acid under the action of UV radiation was studied. IR spectroscopy, thin-layer paper chromatography, and complexometric titration were used to determine the destruction products of these complexons. It was found that the complexons decompose under UV irradiation substantially more easily than ethylenediaminetetraacetic acid does, and the products of their decomposition can undergo a biological utilization under natural conditions. The data obtained in the study make it possible to choose, instead of ethylenediaminetetraacetic acid, ligands that will be nearly fully destructible in the light without deteriorating the ecology.

Method for the production of high-level soluble human recombinant interferon alpha in e. coli and vectors useful for such a production

Method for the production of high-level soluble human recombinant interferon alpha protein (rhuIFNα) in E. coli and vectors useful for such a production. Said method comprises the steps of: (1) Transforming an E. coli selected in the group consisting of E. coli protease deficient host strains, and E. coli reductase deficient host strains, with a recombinant expression vector comprising the sequence encoding the glutathione-S-transferase (GST), a junction sequence including a recognition site for a specific protease and a sequence able to encode an interferon alpha (IFN alpha) protein under the control of an inducible promoter, said vector encoding a GST-IFN alpha fusion protein (2) Expressing said interferon alpha protein in conditions comprising the induction of the expression with 0.1 mM-0.5 mM IPTG and a growth temperature of 25° and/or 37°C, depending on said E. coli strain and (3) Isolating the expressed IFN alpha protein.

Growth Hormone Secretagogue Receptor 1A Ligands

The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.

Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene

The invention relates to isolated polynucleotides homologous with a portion of one strand of the human tumor suppressor gene, FEZ1, and to the tumor suppressor protein encoded thereby, Fez1. The polynucleotides are useful, for example, as probes, primers, portions of expression vectors, and the like. The invention also includes diagnostic, therapeutic, cell proliferation enhancement, and screening methods which involve these polynucleotides and protein. The invention further includes kits useful for performing the methods of the invention.

Cancer-linked gene as target for chemotherapy

Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.

Epad, an oocyte specific protein

The present invention is directed to a human egg specific protein (ePAD), antibodies specific for the human egg specific protein and the use of the ePAD protein to identify antagonists of ePAD activity. Antagonists of ePAD activity are anticipated to have utility as female contraceptive agents.

Chicken growth hormone releasing hormone receptor

The present invention relates to chicken growth hormone releasing hormone (GHRH), its corresponding receptor, and nucleic acid sequences encoding these proteins. More particularly the present invention is directed to the use of the chicken GHRH hormone and its corresponding GHRH receptor to enhance the production of larger, leaner chickens and other avian species used for meat production.

CIS-ELEMENT REGULATING TRANSCRIPTION, TRANSCRIPTIONAL REGULATORY FACTOR BINDING SPECIFICALLY THERETO AND USE OF THE SAME

The present invention provides a novel fructose responsive transcription control cis-element and a transcriptional regulatory factor that interacts therewith, a non-human animal having them transferred or inactivated, a diagnostic method for genetic susceptibility to a metabolic disorder using them, and a screening method for a prophylactic or therapeutic drug for a metabolic disorder using them.

Small peptides having apoptotic activities and their applications

The present invention relates to nine residue peptides (M32-40) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus, to pharmaceutical composition comprising the same and their use for the treatment and/or the prevention of flavivirus-linked infections and cancers.